Article
Multidisciplinary Sciences
Jayoung Ahn, Daniel Duck-Jin Hwang
Summary: This study evaluated longitudinal changes in peripapillary retinal nerve fiber layer (pRNFL) thickness in eyes affected with branch and central retinal vein occlusion (BRVO and CRVO, respectively) and fellow eyes. It found that the global pRNFL thickness of fellow eyes in the BRVO and CRVO groups decreased significantly at 24 months compared to baseline, while the fellow eyes of patients with CRVO had significantly lower pRNFL thickness at 12 and 24 months compared to those of the BRVO and normal control groups. These results suggest that fellow eyes of patients with BRVO and CRVO are susceptible to pRNFL damage.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Pichai Jirarattanasopa, Sakunjanut Jiranoppasakdawong, Mansing Ratanasukon, Patama Bhurayanontachai, Wantanee Dangboon
Summary: This retrospective study evaluated the efficacy of intravitreal dexamethasone implants for treating macular edema associated with retinal vascular diseases. The results showed improvements in visual acuity and central retinal thickness over a 6-month period. Reinjection may be associated with a higher baseline retinal thickness.
Article
Ophthalmology
Meiaad Khayat, Jennifer Perais, David M. Wright, Michael Williams, Noemi Lois
Summary: The study aimed to evaluate anatomic-functional associations at sites of retinal lesions in RVO patients. The results showed decreased retinal sensitivity at sites of RVO lesions, with impaired function in ischemic areas not recovering after treatment and even worsened with reperfusion.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2021)
Article
Cell Biology
Xiaojing Xiong, Xu Chen, Huafeng Ma, Zheng Zheng, Yazhu Yang, Zhu Chen, Zixi Zhou, Jiaxin Pu, Qingwei Chen, Minming Zheng
Summary: Our study identified 60 differential metabolites between RVO-ME patients and controls, as well as 40 differential metabolites between mild and severe RVO-ME patients. Pathway analysis revealed significant alterations in valine, leucine, and isoleucine biosynthesis; ascorbate and aldarate metabolism; and pantothenate and coenzyme A biosynthesis in RVO-ME compared to controls. Adenosine, threonic acid, pyruvic acid, and pyro-L-glutaminyl-l-glutamine were identified as potential biomarkers for distinguishing RVO-ME from controls, while urocanic acid, diethanolamine, 8-butanoylneosolaniol, niacinamide, paraldehyde, phytosphingosine, 4-aminobutyraldehyde, dihydrolipoate, and 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide showed potential for distinguishing between mild and severe RVO-ME.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Ophthalmology
Shinsuke Nakamura, Anri Nishinaka, Yae Hidaka, Masamitsu Shimazawa, Leo Thomas, Remko A. Bakker, Hideaki Hara
Summary: This study investigated the efficacy of Sema3A neutralizing antibody BI-X and/or anti-VEGF therapy in an RVO mouse model. The results showed that BI-X monotherapy and its combination with anti-VEGF therapy had beneficial effects on intraretinal edema and retinal blood flow. Furthermore, BI-X monotherapy normalized the changes in expression of TNF-alpha and semaphorin-related proteins in the RVO mouse model.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2022)
Article
Ophthalmology
Christian M. Ponder, Peyton A. Rather, Mohmed K. Soliman, Sayena Jabbehdari, Adam Neuhouser, Mohammed Z. Siddiqui, Yit C. Yang, Ahmed B. Sallam
Summary: This study aims to compare the visual outcomes and complication rates in eyes with and without retinal vein occlusion (RVO) after phacoemulsification. The results showed that the postoperative visual improvement in eyes with RVO was worse compared to eyes without RVO, and there were also more complications in the RVO group.
JOURNAL OF CATARACT AND REFRACTIVE SURGERY
(2022)
Article
Multidisciplinary Sciences
Yu-Jin Choi, Donghyun Jee, Jin-Woo Kwon
Summary: In this study, we compared the aqueous profiles, baseline characteristics, and clinical outcomes of patients with major branch retinal vein occlusion (BRVO) and macular BRVO. The findings showed that major BRVO patients had higher levels of inflammatory cytokines and VEGF in the aqueous humor, as well as more subretinal fluid, disorganization of retinal inner layers, and ellipsoid zone disruption on optical coherence tomography. Clinically, major BRVO required more intravitreal anti-VEGF injections and had worse visual prognosis in the first 12 months. Additionally, a higher proportion of major BRVO patients required additional treatments after 6 months. Poor responders to anti-VEGF treatment had higher levels of aqueous VEGF and greater central subfield thickness (CST) at baseline.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Hirofumi Sasajima, Masahiro Zako, Rio Maeda, Kenta Murotani, Hidetoshi Ishida, Yoshiki Ueta
Summary: We investigated the impact of baseline foveal intraretinal fluid (IRF) localization on the visual prognosis of branch retinal vein occlusion (BRVO). The results showed that baseline IRF localization significantly correlated with the 12-month best-corrected visual acuity (BCVA), indicating that eyes with better baseline BCVA and one-side IRF have a better visual prognosis in BRVO.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Ophthalmology
Sohan Singh Hayreh
Summary: This article discusses the role of photocoagulation in the treatment of retinal vein occlusion, emphasizing its importance in managing NV and macular edema. Research shows that photocoagulation can prevent and treat NV-related complications in CRVO and BRVO, and recent advancements in treatment options have drastically changed the role and management of photocoagulation in these conditions.
PROGRESS IN RETINAL AND EYE RESEARCH
(2021)
Article
Medical Laboratory Technology
Yikeng Huang, Minli Linghu, Weiwen Hu, Xionggao Huang
Summary: The study found that intravitreal injection of conbercept can effectively improve macular microcirculation and increase retinal blood supply in the treatment of nonischemic BRVO-ME.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2022)
Article
Ophthalmology
Jessica C. Liu, Peter Alsaloum, Amogh I. Iyer, Peter M. Kaiser, Rishi P. Singh
Summary: This study found that patients with Retinal Vein Occlusion (RVO) are at risk for poorer anatomical and visual outcomes after a lapse in anti-vascular endothelial growth factor (VEGF) treatment. Lapse patients experienced an increase in central subfield thickness (CST) that did not fully recover even after treatment was resumed. Additionally, lapse patients had a decrease in best corrected visual acuity (BCVA) after the lapse, but it recovered after 6 months of anti-VEGF treatment.
Article
Medicine, General & Internal
Xuemei Liang, Baiyun Shen, Zuguo Ou, Hongmei An, Li Li
Summary: This study compared the efficacy and injection number of IVR monotherapy and IVR + DEX implants for ME secondary to RVO. The results showed no significant differences in BCVA improvement and CFT reduction between the two groups. However, the IVR + DEX implant group had an advantage in reducing the number of injections and prolonging the time between injections.
FRONTIERS IN MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Xing Du, Yanjuan Sheng, Yeqiang Shi, Min Du, Yuanyuan Guo, Shanshan Li
Summary: This study confirms that the simultaneous use of dexamethasone implant and ranibizumab is safe and effective for the treatment of macular edema secondary to central retinal vein occlusion. The combination treatment significantly improves visual acuity and reduces macular edema, with minimal adverse reactions.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Hirofumi Sasajima, Masahiro Zako, Kenta Murotani, Hidetoshi Ishida, Yoshiki Ueta, Naoko Tachi, Takafumi Suzuki, Yuji Watanabe, Yoshihiro Hashimoto
Summary: We investigated the impact of foveal ellipsoid zone (EZ) status on visual prognosis in eyes with subretinal fluid (SRF) associated with branch retinal vein occlusion (BRVO). We found that baseline intact EZ significantly improved visual prognosis, as its status correlated with the 12-month best-corrected visual acuity (BCVA). The visual acuity of eyes with intact EZ was significantly better than those with disrupted EZ, indicating that foveal EZ status on vertical OCT images can be a novel biomarker for visual prognosis in BRVO-related SRF eyes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Ophthalmology
Yoshihito Sakanishi, Koichi Yasuda, Syu Morita, Keitaro Mashimo, Kazunori Tamaki, Toshiro Sakuma, Nobuyuki Ebihara
Summary: The 24-month study on the efficacy of intravitreal aflibercept (IVA) for macular edema due to branch retinal vein occlusion (BRVO-ME) showed significant improvements in visual acuity and central foveal thickness, with a decrease in injection frequency over time and an increase in ME remission rate. The onset period of the disease was found to be significantly associated with the need for reinjection after 12 months.
JAPANESE JOURNAL OF OPHTHALMOLOGY
(2021)
